An exploratory, open-label study to evaluate the safety and feasibility of ATIR201, a T-lymphocyte enriched leukocyte preparation depleted ex vivo of host alloreactive T-cells (using photodynamic treatment), as adjuvant treatment to a T-cell depleted haploidentical hematopoietic stem cell transplantation in patients with beta-thalassemia major
Phase of Trial: Phase I/II
Latest Information Update: 03 Apr 2017
At a glance
- Drugs ATIR 201 (Primary)
- Indications Thalassaemia
- Focus Adverse reactions; First in man
- Sponsors Kiadis Pharma
- 03 Apr 2017 According to a Kiadis Pharma media release, the company has received regulatory approval from the national authority in Germany to initiate this phase I/II study in Germany.
- 16 Mar 2017 According to a Kiadis Pharma media release, trial design will be presented at the 43rd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT).
- 13 Mar 2017 According to a Kiadis Pharma media release, status changed from planning to recruiting.